PHASE-II STUDY OF SPIROGERMANIUM IN ADVANCED OVARIAN MALIGNANCY
Cancer treatment reports(1981)
摘要
In the present phase II trial 18 heavily pretreated patients with advanced ovarian malignancy were treated with spirogermanium, 11 im and seven iv. Objective responses (partial remission) were obtained in two (11%) of the 18 patients, with a remission duration of 5 and 23 + months, respectively. An additional four (22%) patients had stable disease. Each of these six patients had a better quality of life. There were few side effects. Myelosuppression, nausea, or other gastrointestinal side effects did not occur. The present investigation shows that spirogermanium is useful as a palliative chemotherapeutic agent in patients with advanced ovarian malignancy.
更多查看译文
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要